Randy Strahan
Venture Partner @ Mohr Davidow Ventures
San Francisco, United States
Randy Strahan is a Series A investor at Mohr Davidow Ventures in San Francisco focused on Health Care and Biotechnology. Randy Strahan brings more than 20 years of senior general management and operations experience at leading telecommunications companies to MDV. He helps portfolio companies develop operations strategies and has served as interim CEO at a number of MDV's early stage investments.He currently serves on the board of nLight Photonics.Prior to MDV, Randy was president and CEO of Telmax Communications, a privately held company that manufactures and markets telecommunication equipment to telephone companies such as RBOCs, CLECs and independent telecom companies. Before that, he spent 20 years in various management positions at Pacific Bell, serving most notably as president of Pacific Bell's Service Operations Division where he was responsible for all customer delivery in the company.Randy earned a Bachelor's Degree (summa cum laude) in Criminology from California State University, Fresno.A Master's Degree in Business Administration (MBA) from Chapman College in Orange, California. He also participated in the Sloan Senior Executive Program at Massachusetts Institute of Technology and the Advanced Management Program, Telecommunications, at the University of Southern California.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Randy Strahan invests in
Stages Randy Strahan invests in
Countries Randy Strahan invests in
Investment Focus
Industry
- Health Care 1 (33%)
- Biotechnology 1 (33%)
- Health Diagnostics 1 (33%)
Stage
- Series A 1 (33%)
- Series C 1 (33%)
- Series D 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tethys BioScience
|
Tethys BioScience, Inc. engages in the discovery, development, and commercialization of biological markers. Its products are used to diagnosis the metabolic diseases, such as diabetes. The company offers PreDx Diabetes Risk Test, a diagnostic test that analyzes a set of multiple proteins and other blood borne biomarkers implicated in thedevelopment of diabetes. Tethys BioScience, Inc. was founded in 2002 and is based in Emeryville, California. | $25M / Series D / Nov 09, 2009 | |
|
Tethys BioScience
|
Tethys BioScience, Inc. engages in the discovery, development, and commercialization of biological markers. Its products are used to diagnosis the metabolic diseases, such as diabetes. The company offers PreDx Diabetes Risk Test, a diagnostic test that analyzes a set of multiple proteins and other blood borne biomarkers implicated in thedevelopment of diabetes. Tethys BioScience, Inc. was founded in 2002 and is based in Emeryville, California. | Series C / Jan 10, 2008 | |
|
Tethys BioScience
|
Tethys BioScience, Inc. engages in the discovery, development, and commercialization of biological markers. Its products are used to diagnosis the metabolic diseases, such as diabetes. The company offers PreDx Diabetes Risk Test, a diagnostic test that analyzes a set of multiple proteins and other blood borne biomarkers implicated in thedevelopment of diabetes. Tethys BioScience, Inc. was founded in 2002 and is based in Emeryville, California. | $5.4M / Series A / Oct 31, 2005 |
Co-Investors
Kleiner Perkins
2 deals together
Aeris Capital
1 deal together
Greenspring Associates
1 deal together
Intel Capital
1 deal together
Wasatch Advisors
1 deal together
About Mohr Davidow Ventures
For 30 years the _Mohr Davidow Ventures team has invested in early stage technology-based startups that redefine or create large new markets. They believe that emerging information technology innovations are enabling a decade-long opportunity to invest in the “Era of Digital Engagement,” one in which personal, commercial, and public sectorinteractions of all kinds will be profoundly reengineered to leverage the power of mobile devices, cloud computing, and data analytics. The Firm seeks to identify and partner with exceptional entrepreneurs who leverage these technologies to build companies where seamless, deep engagement with customers will create billion dollar markets in a number of different verticals. These verticals include: Digital Marketing, Advertising, & Media, Collaborative Enterprise Applications, The Digitization of Education and Health, Digital Financial Services, E‐commerce & Digital Retail Innovation, Mobile/Web‐Powered “LifeTech.” The Firm also has previous investments in the innovative life sciences & genomics space.Leading companies funded by Mohr Davidow Ventures includes: Agile (Acquired by NYSE: ORCL); Aryaka Networks; Brocade; Coupa; Genomatica; HealthTap; Infusionsoft; Kabbage; nLight; ONI Systems (Acquired by NASDAQ: CIEN); Proofpoint (NASDAQ: PFPT); Rally Software (NYSE: RALY); Rocket Fuel (NASDAQ: FUEL); Rambus; Shutterfly (NASDAQ: SFLY); Ticketfly; Verinata Health (Acquired by NASDAQ: ILMN); and Visible Measures. The Firm has $1.85 billion under management.
Mohr Davidow Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Nancy Schoendorf
Managing Partner
|
|||
|
Randy Strahan
Venture Partner
|
|||
Bill Davidow
Partner Emeritus
|
|||
Bill Ericson
General Partner
|
|||
Bryan Stolle
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Randy Strahan invest in?
Randy Strahan invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Series A and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Randy Strahan last invest?
The most recent investment recorded for Randy Strahan closed in Nov 2009. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
